AstraZeneca and Daiichi Sankyo said Monday they received FDA approval for their [fam-] trastuzumab deruxtecan-nxki, which will be marketed as Enhertu. [Fam-] trastuzumab deruxtecan is an antibody–drug conjugate (ADC) designed to delivery cytotoxic chemotherapy to cancer cells via a human epidermal receptor 2 (HER2) antibody attached to a novel topoisomerase I inhibitor payload and a tetrapeptide-based linker.
AstraZeneca and Daiichi Sankyo said Monday they received FDA approval for their [fam-] trastuzumab deruxtecan-nxki, which will be marketed as Enhertu. [Fam-] trastuzumab deruxtecan is an antibody—drug conjugate (ADC) designed to delivery cytotoxic chemotherapy to cancer cells via a human epidermal receptor 2 (HER2) antibody attached to a novel topoisomerase I inhibitor payload and a tetrapeptide-based linker.
The approval is for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received 2 or more prior anti-HER2-based regimens.
The company recently presented results from its pivotal phase 2 study, DESTINY-Breast01, at the at the San Antonio Breast Cancer Symposium in San Antonio, Texas and also published in The New England Journal of Medicine.
The companies said in a statement the clearance came under Accelerated Approval based on tumor response rate and duration of response. “Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial,” the companies said.
In DESTINY, 184 female patients with HER2-positive metastatic breast cancer received 5.4 mg/kg of Enhertu as a monotherapy; all patients previously were treated with prior trastuzumab, ado-trastuzumab emtansine, and 66% had prior pertuzumab.
The phase 2 trial results showed a confirmed objective response rate of 60.3% (n = 111; 95% CI, 52.9-67.4), including a 4.3% complete response rate (n = 8) and a 56.0% partial response rate (n = 103). A median duration of response of 14.8 months (95% CI, 13.8-16.9) was demonstrated as of August 1, 2019.
In addition, patients had a median progression-free survival of 16.4 months (95% CI, 12.7-not estimable), based upon a median duration of follow-up of 11.1 months.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Addressing Patent Abuse, Reimbursement Models Key to Sustainable Biosimilar Market
April 25th 2025Sonia T. Oskouei, PharmD, emphasized strategies to streamline regulations and evolve to overcome barriers and expand the availability of cost-effective biosimilar treatments across more therapeutic areas.
Unlocking Biosimilar Potential in Specialty Pharmacies With Legislative Support, Formulary Changes
April 24th 2025Sophia Humphreys, PharmD, MHA, BCBBS, emphasized that legislative support and formulary changes are crucial for overcoming unique challenges in specialty pharmacies and driving the growth of biosimilar adoption, which has significant cost saving potential in the next decade.